• Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsCorporate GovernanceArticles of Association

Investors

  • Overview
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads

Articles of Association

§ 1 The name of the company

The name of the company is Immunicum AB (publ). The company is a public company (publ).

§ 2 Registered office

The board of directors shall have its registered office in Göteborgs municipality, Västra Götalands county.

§ 3 Object of the company

The company shall conduct research, development, marketing and sales of pharmaceuticals and thereby comparable business.

§ 4 Share capital

The share capital shall constitute a minimum of SEK 8 000 000 and a maximum of SEK 32 000 000 .

§ 5 Number of shares

The number of shares shall be minimum 160 000 000 and maximum 640 000 000.

§ 6 Board of directors

The board of directors shall consist of a minimum of three and a maximum of eight members without deputies.

§ 7 Auditors

For auditing of the company’s annual report, the accounting records and the administration of the board of directors and the managing director, an auditor is appointed each year at the annual general meeting for the period until the end of the next annual general meeting.

§ 8 Place of shareholders’ meeting

The shareholders’ meeting shall be held in Gothenburgs municipality or Stockholms municipality.

§ 9 Notice of summons

Notice of summons to the annual general meeting shall be made through an announcement in Post- och Inrikes Tidningar and by making the notice available on the company’s website. Simultaneously with the notice, the company shall by way of announcement in Dagens Industri inform that notice has been made. Notice of summons to the annual general meeting and an extraordinary general meeting where a matter of amendment of the articles of association shall be resolved shall be made at earliest six and not later than four weeks prior the meeting. Notice of summons to other extraordinary general meetings shall be made at earliest six and not later than three weeks prior to the extraordinary general meeting.

§ 10 Notice to attend general meeting

Shareholders have the right to attend the general meeting if they are recorded in the share register in accordance with the provisions in Chapter 7 Section 28 Paragraph 3 of the Companies Act and have given notice of their attendance to the company no later than the day mentioned in the notice. Such day may not be a Sunday, any other public holiday, Saturday, Midsummers Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth working day prior to the meeting.

§ 11 Agenda at the annual general meeting

At the annual general meeting shall the following items be addressed:
1. Election of chairman of the general meeting.
2. Preparation and approval of voting register.
3. Presentation and approval of the agenda.
4. Election of one or two persons to check the minutes.
5. Control if the meeting has been duly convened.
6. Presentation of the annual report and the audit report and, if applicable, the consolidated annual report and consolidated audit report.
7. Decisions
a) on confirmation of the income statement and balance sheet and, if applicable, the group income statement and group balance sheet.
b) on disposition of the company’s profit or loss according to the adopted balance sheet.
c) discharge of liability for the board of directors and the managing director.
8. Determination of remuneration for the directors of the board of directors and auditors.
9. Election of directors of the board of directors and auditors and, if applicable, deputy auditors.
10. Other matters that are to be addressed at the annual general meeting pursuant to the Companies Act or the articles of association.

§ 12 Financial year

The company’s financial year shall be 1 January – 31 December

§ 13 Record company

The company’s shares shall be registered in a securities register pursuant to the Swedish Financial Instruments Accounts Act (1998:1479).


Adopted by the Extraordinary General Meeting 2020-12-18

Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 (0)8 732 8400

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2021 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve